Signum names Shroot as CEO

Signum Biosciences has appointed Braham Shroot, formerly CSO of Barrier Therapeutics, as CEO. Shroot replaces Gregory Stock, who will continue to remain active with the company as a member of the board. Signum release

Renhuang Pharmaceuticals has announced that company CFO Yan Yi Chen has resigned for personal reasons effective immediately. Renhuang release

Orexo has appointed Robin Wright as EVP head of finance, replacing Claes Wenthzel who, after five years in the group, has decided to leave the company for other assignments. Orexo release

Invida Group has added three new members to the senior management team. Invida has appointed Sumeet Sud has been named chief marketing officer, a newly created position. In addition, Girdhar Balwani and Thomas Birsinger have been named country managers for India and Vietnam, respectively. Invida release

The International AIDS Vaccine Initiative has tapped Michael Caulfield as executive director of the IAVI AIDS Vaccine Design and Development Laboratory. IAVI release

CorMedix has appointed Robert Hopkins as head of clinical operations and project management and Dilip Wadgaonkar as head of product development and manufacturing. CoreMedix release

Robert Baldini has been elected to K-V Pharmaceutical's board by a unanimous vote. K-V release

Hana Biosciences has announced the appointment of Robert (Bob) Spiegel to the company's board. Spiegel was employed at Schering Plough for 26 years where he was deeply involved in clinical research culminating with his position as CMO. Hana release

Novavax has announced the appointment of Richard Douglas to its board of directors. Douglas is currently senior VP, corporate development at Genzyme. Novavax release

Generex Biotechnology has named Craig Eagle to its scientific advisory board. Generex release

Bionovo has appointed James Pickar to its medical advisory board. Bionovo release

Quantum Immunologics has announced that Wilhelmina Tribble is joining the board as the sixth independent board member. Quantum release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.